Featured News

Phase III Study Completes Patient Recruitment

On May 2, 2017 Ablynx announced that it has successfully completed patient recruitment in the multi-national, double-blind, placebo-controlled Phase III HERCULES study of caplacizumab to treat acquired TTP. If approved, this drug will be the first therapeutic specifically indicated for the disease.

View the full press release.

Rare Disease Day February 28th

Today, events are occurring around the world to recognize rare diseases.   What a great time for you to get involved in supporting a rare disease by making a difference.  This year Rare Disease Day has created a theme around RESEARCH, with a slogan of 'With research, possibilities are limitless'.